{"id":72260,"date":"2026-08-11T12:39:33","date_gmt":"2026-08-11T04:39:33","guid":{"rendered":"https:\/\/flcube.com\/?p=72260"},"modified":"2026-08-11T12:39:35","modified_gmt":"2026-08-11T04:39:35","slug":"beone-medicines-announces-imdelltra-tarlatamab-first-in-class-dll3-cd3-t-cell-engager-co-developed-with-amgen-enters-clinical-use-across-17-chinese-cities","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72260","title":{"rendered":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BeOne Medicines Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6160:HKG\">HKG: 6160<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688235:SHA\">SHA: 688235<\/a>)<\/strong> announced that <strong>Imdelltra (tarlatamab for injection)<\/strong> \u2014 co\u2011developed and commercialized in Mainland China with <strong>Amgen (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AMGN:NASDAQ\">NASDAQ: AMGN<\/a>)<\/strong> \u2014 has officially entered clinical use. As of <strong>August 10<\/strong>, medical institutions across <strong>17 cities in China<\/strong> have issued prescriptions for tarlatamab, totaling <strong>29 medical institutions<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-commercial-launch-overview\" class=\"wp-block-heading\">Commercial Launch Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Imdelltra (tarlatamab for injection)<\/td><\/tr><tr><td><strong>Partners<\/strong><\/td><td>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) \u00d7 Amgen (NASDAQ: AMGN)<\/td><\/tr><tr><td><strong>China Commercial Supply Launch<\/strong><\/td><td>7 Aug 2026<\/td><\/tr><tr><td><strong>Clinical Use Confirmed<\/strong><\/td><td>11 Aug 2026 (prescriptions as of 10 Aug 2026)<\/td><\/tr><tr><td><strong>Initial Coverage<\/strong><\/td><td>17 cities, 29 medical institutions issuing prescriptions<\/td><\/tr><tr><td><strong>Initial Batch Target<\/strong><\/td><td>80 cities nationwide; 200+ medical institutions<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult patients with previously treated extensive\u2011stage small cell lung cancer (ES\u2011SCLC)<\/td><\/tr><tr><td><strong>Distinction<\/strong><\/td><td>First and currently only approved <strong>T\u2011cell engager (TCE)<\/strong> targeting <strong>DLL3 and CD3<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-prescribing-institutions\" class=\"wp-block-heading\">Prescribing Institutions<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medical institutions across 17 cities in China have issued prescriptions for tarlatamab as of August 10, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shanghai Chest Hospital<\/strong><\/li>\n\n\n\n<li><strong>Shanghai Pulmonary Hospital<\/strong><\/li>\n\n\n\n<li><strong>Fudan University Shanghai Cancer Center<\/strong><\/li>\n\n\n\n<li><strong>Cancer Hospital, Chinese Academy of Medical Sciences<\/strong><\/li>\n\n\n\n<li><strong>Peking University Cancer Hospital<\/strong><\/li>\n\n\n\n<li><strong>Beijing GoBroad Hospital<\/strong><\/li>\n\n\n\n<li><strong>Sun Yat\u2011sen University Cancer Center<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In total, <strong>29 medical institutions<\/strong> have prescribed the therapy to date.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Tarlatamab (Imdelltra), a <strong>T\u2011cell engager (TCE)<\/strong> bispecific antibody<\/li>\n\n\n\n<li><strong>Targets:<\/strong> <strong>DLL3<\/strong> (expressed on small cell lung cancer cells) and <strong>CD3<\/strong> (on T cells)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Bridges DLL3\u2011expressing tumor cells with T cells, redirecting the patient&#8217;s own immune system to kill SCLC cells<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Status:<\/strong> The <strong>first and currently only approved TCE targeting DLL3 and CD3<\/strong>, with no competing TCE in this class currently approved<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of adult patients with <strong>previously treated extensive\u2011stage small cell lung cancer (ES\u2011SCLC)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-rollout-plan\" class=\"wp-block-heading\">Rollout Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Coverage<\/th><\/tr><\/thead><tbody><tr><td><strong>Current (as of 10 Aug 2026)<\/strong><\/td><td>17 cities, 29 prescribing medical institutions<\/td><\/tr><tr><td><strong>Initial Batch Rollout<\/strong><\/td><td>80 cities nationwide, 200+ medical institutions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage:<\/strong> As the <strong>first and only approved DLL3\/CD3 T\u2011cell engager<\/strong>, tarlatamab faces no direct in\u2011class competition in China, positioning it to define the standard of care for previously treated ES\u2011SCLC.<\/li>\n\n\n\n<li><strong>High Unmet Need:<\/strong> Extensive\u2011stage SCLC carries a poor prognosis, with limited treatment options after first\u2011line therapy \u2014 a setting where improved survival outcomes represent significant clinical value.<\/li>\n\n\n\n<li><strong>Rapid Commercial Scale\u2011Up:<\/strong> Moving from commercial supply launch (7 Aug) to prescriptions in 17 cities within days, with an initial batch covering <strong>80 cities and 200+ institutions<\/strong>, signals strong hospital\u2011access momentum.<\/li>\n\n\n\n<li><strong>Partnership Validation:<\/strong> The launch underscores the commercial execution of the <strong>BeOne\u2013Amgen<\/strong> collaboration in Mainland China, combining Amgen&#8217;s global development heritage with BeOne&#8217;s local commercial infrastructure.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding tarlatamab&#8217;s commercial rollout, hospital coverage expansion, and clinical adoption in China. Actual results may differ due to risks including market access, reimbursement dynamics, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[330,2092,16,847,40,912,3046,848,2790],"class_list":["post-72260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-beone-medicines","tag-cancer","tag-hkg-6160","tag-market-launch","tag-nasdaq-amgn","tag-nasdaq-onc","tag-sha-688235","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72260\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72260\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T04:39:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T04:39:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\\\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities\",\"datePublished\":\"2026-08-11T04:39:33+00:00\",\"dateModified\":\"2026-08-11T04:39:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1102.webp\",\"keywords\":[\"Amgen\",\"BeOne Medicines\",\"Cancer\",\"HKG: 6160\",\"Market launch\",\"NASDAQ: AMGN\",\"NASDAQ: ONC\",\"SHA: 688235\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72260#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72260\",\"name\":\"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\\\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1102.webp\",\"datePublished\":\"2026-08-11T04:39:33+00:00\",\"dateModified\":\"2026-08-11T04:39:35+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72260\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Announces Imdelltra (Tarlatamab), First\u2011in\u2011Class DLL3\\\/CD3 T\u2011Cell Engager Co\u2011Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72260#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\\\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72260","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.","og_url":"https:\/\/flcube.com\/?p=72260","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-11T04:39:33+00:00","article_modified_time":"2026-08-11T04:39:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72260#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72260"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities","datePublished":"2026-08-11T04:39:33+00:00","dateModified":"2026-08-11T04:39:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72260"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72260#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","keywords":["Amgen","BeOne Medicines","Cancer","HKG: 6160","Market launch","NASDAQ: AMGN","NASDAQ: ONC","SHA: 688235","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72260#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72260","url":"https:\/\/flcube.com\/?p=72260","name":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72260#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72260#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","datePublished":"2026-08-11T04:39:33+00:00","dateModified":"2026-08-11T04:39:35+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) \u2014 co\u2011developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) \u2014 has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72260#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72260"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72260#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","width":1080,"height":608,"caption":"BeOne Medicines Announces Imdelltra (Tarlatamab), First\u2011in\u2011Class DLL3\/CD3 T\u2011Cell Engager Co\u2011Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72260#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3\/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72260"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72260\/revisions"}],"predecessor-version":[{"id":72263,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72260\/revisions\/72263"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72262"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}